PHENIX Trial Demonstrates Sentinel Lymph Node Biopsy Alone is Noninferior to Full Lymphadenectomy in Early-Stage Cervical Cancer
核心洞察
The Chinese phase III PHENIX trial found that sentinel lymph node biopsy alone was noninferior to lymphadenectomy for disease-free survival in women with early-stage cervical cancer (搜索).
Patients who received biopsy-only treatment had significantly fewer surgical complications including lymphocyst (搜索), lymphedema (搜索), paresthesia (搜索), and pain compared to those undergoing full lymphadenectomy.
The study enrolled 838 patients with negative sentinel lymph nodes (搜索) between December 2015 and December 2023, with median follow-up of 62.8 months.
A landmark Chinese phase III trial has demonstrated that sentinel lymph node biopsy (SLNB) alone is noninferior to full pelvic lymphadenectomy in women with early-stage cervical cancer (搜索), while significantly reducing surgical complications. The PHENIX trial, published in The New England Journal of Medicine, challenges the standard surgical approach and offers a less invasive alternative for patients with node-negative disease.
Trial Design and Patient Population
The open-label multicenter trial enrolled patients between December 2015 and December 2023. A total of 838 patients with stage I–IIA1 cervical carcinomas and negative sentinel lymph nodes (搜索) were intraoperatively randomized in a 1:1 ratio to either undergo bilateral pelvic lymphadenectomy (418 patients) or receive biopsy-only treatment (420 patients). All patients underwent radical hysterectomy, with biopsy performed at the time of surgery followed by examination of frozen sections.
The primary endpoint was disease-free survival at 3 years, with a noninferiority margin of 5 percentage points in the upper limit of the confidence interval for the difference between the lymphadenectomy group and the biopsy-only group.
Efficacy Outcomes
With a median follow-up of 62.8 months, the trial met its primary endpoint. Disease-free survival at 3 years was 96.9% in the biopsy-only group compared to 94.6% in the lymphadenectomy group, representing a difference of −2.3 percentage points (95% CI = −5.0% to 0.5%, P < .001 for noninferiority).
Notably, cervical cancer (搜索)–specific survival at 3 years favored the biopsy-only approach, with 99.2% survival compared to 97.8% in the lymphadenectomy group (hazard ratio for cancer death in competing-risks analysis = 0.37, 95% CI = 0.15–0.95).
Retroperitoneal nodal recurrences occurred in no patients in the biopsy-only group versus nine patients (2.2%) in the lymphadenectomy group, suggesting that omitting lymphadenectomy does not compromise oncologic outcomes.
Safety Profile and Complications
The safety advantages of the biopsy-only approach were substantial. Compared with the lymphadenectomy group, patients who received SLNB alone experienced significantly lower rates of multiple surgical complications:
- Lymphocyst: 8.3% versus 22.0% (P < .001)
- Lymphedema: 5.2% versus 19.1% (P < .001)
- Paresthesia: 4.0% versus 8.4% (P = .009)
- Pain: 2.6% versus 7.9% (P = .001)
Clinical Implications
The findings address a longstanding question in cervical cancer (搜索) surgery, given that the majority of patients with early-stage disease do not have lymph node involvement. Pelvic lymphadenectomy, while part of the standard surgical approach, carries significant morbidity and mortality risks that may be unnecessary for many patients.
"In patients with early-stage cervical cancer (搜索), SLNB alone was noninferior to lymphadenectomy with respect to disease-free survival and was associated with fewer complications," concluded the investigators led by corresponding author Jihong Liu, MD, PhD, of Sun Yat-sen University Cancer Center (搜索) in Guangzhou, China.
The PHENIX trial provides compelling evidence that sentinel lymph node mapping can effectively identify node-negative patients who can safely avoid the morbidity associated with full pelvic lymphadenectomy, potentially transforming the surgical management of early-stage cervical cancer (搜索).